Correlation Between Fate Therapeutics and Humacyte

Can any of the company-specific risk be diversified away by investing in both Fate Therapeutics and Humacyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fate Therapeutics and Humacyte into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Fate Therapeutics and Humacyte, you can compare the effects of market volatilities on Fate Therapeutics and Humacyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fate Therapeutics with a short position of Humacyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fate Therapeutics and Humacyte.

Diversification Opportunities for Fate Therapeutics and Humacyte

0.33

Correlation Coefficient

Fate Therapeutics  Humacyte

Weak diversification

The 3 months correlation between Fate and Humacyte is 0.33. Overlapping area represents the amount of risk that can be diversified away by holding Fate Therapeutics and Humacyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Humacyte and Fate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fate Therapeutics are associated (or correlated) with Humacyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Humacyte has no effect on the direction of Fate Therapeutics i.e., Fate Therapeutics and Humacyte go up and down completely randomly.

Pair Corralation between Fate Therapeutics and Humacyte

Given the investment horizon of 90 days Fate Therapeutics is expected to under-perform the Humacyte. But the stock apears to be less risky and, when comparing its historical volatility, Fate Therapeutics is 1.68 times less risky than Humacyte. The stock trades about -0.08 of its potential returns per unit of risk. The Humacyte is currently generating about 0.1 of returns per unit of risk over similar time horizon. If you would invest  51.00  in Humacyte on October 2, 2024 and sell it today you would earn a total of  131.00  from holding Humacyte or generate 256.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Fate Therapeutics  vs.  Humacyte

Fate Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Humacyte

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Humacyte are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Humacyte showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Fate Therapeutics and Humacyte

The main advantage of trading using opposite Fate Therapeutics and Humacyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fate Therapeutics position performs unexpectedly, Humacyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Humacyte will offset losses from the drop in Humacyte's long position.

The idea behind Fate Therapeutics and Humacyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.